Tuesday, 9 August 2022
  
Login

Australia's most trusted
source of pharma news

Tuesday, 09 August 2022
Listen to this story 
News

BMS rips up deal amid cartel worry

Posted 4 August 2022 AM

In a potentially bad sign for early entry deals for generics and biosimilars, BMS subsidiary Celgene and generics companies Juno and Natco have withdrawn their application to the ACCC to authorise their agreement.

In March this year the ACCC indicated it would reject an application by the companies to approve a deal that gave Juno the rights to sell generics of multiple myeloma treatment,Revlimid, before patents expired, in exchange for dropping litigation.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (11)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.